Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Green Door turned out to be a big red door
LOLOLOL
We have a winner....
Dreams do come true....
That and the G and N shares is undeniable proof. I am all in tomorrow. DoLOLland here we come.
If I read it correctly, then yes.
Looks like 20 days unless there is an amendment filed before it becomes effective then it is 20 days from the amendment...
https://www.law.cornell.edu/uscode/text/15/77h
This statement is on page 2 of the S3
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.
The answer lies in Section 8 (a) of the Securities Act or 1933. Will google that section and see what it says.
Now this post should be a sticky....
It could be a short-term benefit as it would generate hype but long-term it can actually hurt them as it would benefit pharmaceutical companies over Mom and Pop dispensary
Hmmm, nonwhere did I did say it was debt or tried to pass it off as debt when I clearly stated deficit. I said deficit and meant deficit. They are $50 million in the hole. That means they spent $50 million dollars more than they taken in. Where did that 50 million go?
The Green Door PR is being held up because they painted it RED.
TRTC does have a $50 million dollar defecit. Where did all that money go?
You can go to her Facebook page yourself to verify....
Why does Derek Peterson have an AKA Derek Opedisano?
Wasn't a big surprise to everyone else....
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
May 17, 2016 09:00:00 (ET)
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
AXIM's CBG Clinical Trials Led by World-Renowned Dermatologist and Specialist on Psoriasis and Eczema, Dr. Meinardi, at The Maurits Clinics in The Hague, The Netherlands
NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- AXIM(R) Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema. Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.
AXIM's CEO, Dr. George Anastassov, states, "We are extremely pleased that our ongoing efforts in finding solutions to conditions for which there are no effective treatments or the ones available are associated with significant side effects (e.g. immunosuppression) are culminating with the clinical trials of our Renecann(TM) product. Psoriasis and atopic dermatitis are debilitating conditions causing significant decrease in quality of life. Utilizing our proprietary technologies and incorporating unique cannabinoids, we believe that we will be able to effectively address these concerns."
Lekhram Changoer MSc, BSc, AXIM(R) Chief Technology Officer, states, "We are very excited to begin human dermatological trials for psoriasis and eczema at The Maurits Clinics. Dr. Meinardi is a highly experienced professional and we are glad that his interests are aligned with ours in the utilization of different cannabinoids as the API for finding safe solutions for people with these skin disorders. The AXIM(R) AX-1602 ointment will be tested with different concentrations of cannabinoids and will be placebo controlled. Following the successful completion of this clinical trial, AXIM(R) products will be registered as an ointment for various skin disorders."
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients' quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other acute (infection) and chronic illnesses. Although a number of treatment options exist for PsO, there continues to be significant unmet need on the market. The psoriasis market will grow to $10.4 Billion by 2020.
Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thicken over time. It typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As the affected children get older, the back of the knees and front of the elbows are the most common areas affected. In adults, the hands and feet are most commonly affected. Scratching worsens symptoms and affected people have an increased risk of skin infections. According to the Atopic Dermatitis - Epidemiology Forecast to 2024, there will be 67,630,097 atopic dermatitis cases, and atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022.
AXIM Leads Global Cannabinoid Research and Development:
Cannabigerol (CBG) "the stem cell cannabinoid" has a broad range of biological efficacies. It is a non-psychoactive cannabinoid found in the plant genus Cannabis. Cannabigerol has been found to act as a high affinity (2) -adrenergic receptor agonist, moderate affinity 5-HT(1A) receptor antagonist, and low affinity CB(1) receptor antagonist. CBG has also been found to have an anti-nausea and anti-emetic (anti-vomiting) effects.
Further, CBG has demonstrated an anti-inflammatory effect, has also been shown to reduce pain, ease symptoms of psoriasis, act as an antibacterial agent and even slow the proliferation of tumor cells in vitro and in-vivo.
About Dr. Marcus Meinardi:
Dr. Marcus Meinardi has worked since 2005 as a dermatologist at the Maurits Clinics in The Hague, The Netherlands. Dr. Meinardi studied medicine in Rotterdam and then followed his training in Dermatology at the University of Amsterdam. In 1992, he became head of the Department of Dermatology and Allergy. Dr. Meinardi completed his PhD thesis on treatment of psoriasis.
Photos accompanying this release are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b38b7454-d0df-467e-a10f-6c679bc8d9fa
http://www.globenewswire.com/NewsRoom/AttachmentNg/2a7ea20c-f735-4d76-a457-a03dcf0652a0
A world leader in cannabis-based drug development, AXIM(R) Biotech's core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 888-829-0070.
About AXIM Biotechnologies:
AXIM(R) Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM(R) Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
These photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227
(MORE TO FOLLOW) Dow Jones Newswires
May 17, 2016 09:00 ET (13:00 GMT)
HUGE NEWS FOR MJNA PORTFOLIO COMPANY AXIM
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
May 17, 2016 09:00:00 (ET)
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
AXIM's CBG Clinical Trials Led by World-Renowned Dermatologist and Specialist on Psoriasis and Eczema, Dr. Meinardi, at The Maurits Clinics in The Hague, The Netherlands
NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- AXIM(R) Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema. Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.
AXIM's CEO, Dr. George Anastassov, states, "We are extremely pleased that our ongoing efforts in finding solutions to conditions for which there are no effective treatments or the ones available are associated with significant side effects (e.g. immunosuppression) are culminating with the clinical trials of our Renecann(TM) product. Psoriasis and atopic dermatitis are debilitating conditions causing significant decrease in quality of life. Utilizing our proprietary technologies and incorporating unique cannabinoids, we believe that we will be able to effectively address these concerns."
Lekhram Changoer MSc, BSc, AXIM(R) Chief Technology Officer, states, "We are very excited to begin human dermatological trials for psoriasis and eczema at The Maurits Clinics. Dr. Meinardi is a highly experienced professional and we are glad that his interests are aligned with ours in the utilization of different cannabinoids as the API for finding safe solutions for people with these skin disorders. The AXIM(R) AX-1602 ointment will be tested with different concentrations of cannabinoids and will be placebo controlled. Following the successful completion of this clinical trial, AXIM(R) products will be registered as an ointment for various skin disorders."
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients' quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other acute (infection) and chronic illnesses. Although a number of treatment options exist for PsO, there continues to be significant unmet need on the market. The psoriasis market will grow to $10.4 Billion by 2020.
Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, which often thicken over time. It typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As the affected children get older, the back of the knees and front of the elbows are the most common areas affected. In adults, the hands and feet are most commonly affected. Scratching worsens symptoms and affected people have an increased risk of skin infections. According to the Atopic Dermatitis - Epidemiology Forecast to 2024, there will be 67,630,097 atopic dermatitis cases, and atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022.
AXIM Leads Global Cannabinoid Research and Development:
Cannabigerol (CBG) "the stem cell cannabinoid" has a broad range of biological efficacies. It is a non-psychoactive cannabinoid found in the plant genus Cannabis. Cannabigerol has been found to act as a high affinity (2) -adrenergic receptor agonist, moderate affinity 5-HT(1A) receptor antagonist, and low affinity CB(1) receptor antagonist. CBG has also been found to have an anti-nausea and anti-emetic (anti-vomiting) effects.
Further, CBG has demonstrated an anti-inflammatory effect, has also been shown to reduce pain, ease symptoms of psoriasis, act as an antibacterial agent and even slow the proliferation of tumor cells in vitro and in-vivo.
About Dr. Marcus Meinardi:
Dr. Marcus Meinardi has worked since 2005 as a dermatologist at the Maurits Clinics in The Hague, The Netherlands. Dr. Meinardi studied medicine in Rotterdam and then followed his training in Dermatology at the University of Amsterdam. In 1992, he became head of the Department of Dermatology and Allergy. Dr. Meinardi completed his PhD thesis on treatment of psoriasis.
Photos accompanying this release are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b38b7454-d0df-467e-a10f-6c679bc8d9fa
http://www.globenewswire.com/NewsRoom/AttachmentNg/2a7ea20c-f735-4d76-a457-a03dcf0652a0
A world leader in cannabis-based drug development, AXIM(R) Biotech's core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 888-829-0070.
About AXIM Biotechnologies:
AXIM(R) Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM(R) Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
These photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227
(MORE TO FOLLOW) Dow Jones Newswires
May 17, 2016 09:00 ET (13:00 GMT)
I heard the Green Door PR has been cancelled because they changed the color of the door to RED!
MY GAWD!!!!
I must be dreaming.
I think you mean even without dilution, the lights would be off as even Edible Gardens lost money and has never had a net profit.
*Allegedly fired for being pregnant.
There is No alternative.
Oh come on. They created the G and N class of shares. It is so obvious it stands for Green. OPEN THE GREEN DOOR. EPIC BLASTOFF, DOLLOARLAND GUARANTEED!!!!!
Did you seen the addition of the new U and F series perfered shares. It can only mean ine thing. Joint Venture with University of Florida. Do the math.
WHAT A STRONG TRADING DAY TODAY! GREAT SIGN!
Yes, I agree with you there. It needs to be descheduled, not rescheduled as rescheduling still leaves it as a controlled substance. Basically rescheduling would still leave it up to Federal control and rules and regulations and would do nothing to change the current state/federal conflicts.
Yes, the doctor determines the EXACT does, like 1 mg 3 times a day etc. And you would have to take it to an FDA pharmacy which will only be able to dispense a drug that has strict quality controls that received FDA approval to manufacture and distribute said pharmaceutical preparation. It wouldn't be from mom and pop dispensaries, it would be through pharmacies. Just like Oxcycontin has to be dispensed by a pharmacist and can only dispense the pills from an FDA approve pharmaceutical source and not from a lab he has in the back of the store.
No, the makers of Oxycontin wouldn't be considered trafficking a schedule 2 drug as they have FDA and DEA approval to manufacture and sell it.
Yes, legally prescribed, but only for FDA approved conditions and for a precise dosage and quantity and through an FDA approved and licensed pharmacy and only from an FDA approved manufacturer.
I can't take my prescription from my physician for oxycodone and have just anybody manufacture it and sell it to me.
Schedule 2 will not decriminalize it. It would put it on the same level as Cocaine and Oxycontin. It would still be a federally controlled substance. It needs to be descheduled and treated like alcohol. Rescheduling is a win for big pharma, not TRTC.
No, the S3 was filed after Blum Oakland....
Oh...got ya.
.15 and this time I want my lab coat when it hits
I think you mean MJ.
Shouldn't there have been either an 8k or at least a PR notifying shareholders of a product recall or temporary halt in production? I think they breached fiduciary dury with that one.
I wonder what the sentiment would be if say TRTC took out a loan and put up Blum as collateral, defaulted on that loan and had Blum seized in foreclosure, and then DP and MJ then purchased Blum at auction for a different entity that they owned.
BREAKING NEWS!! TRTC JUST CREATED PERFERED SHARES CLASSES D AND E. IT CAN ONLY MEAN ONE THING. DO THE MATH. DIXIE ELIXIRS IS A DONE DEAL.
Kauffman is still very involved and his wife is Salwa Ibrahim, she is the person the MJ permit in Oakland is under.